Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metoprolol + diltiazem
- Development stage
- Discontinued
- Lead developer
- US Pharmaceuticals Holdings I
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of two cardiovascular medications - metoprolol (a beta-blocker) and diltiazem (a calcium channel blocker). While both drugs are individually used to treat conditions like hypertension and atrial fibrillation, their combination is generally approached with caution due to potentially serious drug interactions. The combination can cause enhanced negative effects on heart rate, blood pressure, and cardiac conduction, potentially leading to bradycardia, hypotension, heart block, or heart failure.
02
Targets
ADRB1 (β1)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on metoprolol + diltiazem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metoprolol + diltiazem.